Canada - English - Health Canada

sandoz canada incorporated - dexamethasone phosphate (dexamethasone sodium phosphate) - solution - 10mg - dexamethasone phosphate (dexamethasone sodium phosphate) 10mg - adrenals

Canada - English - Health Canada

juno pharmaceuticals corp. - dexamethasone phosphate (dexamethasone sodium phosphate) - solution - 10mg - dexamethasone phosphate (dexamethasone sodium phosphate) 10mg

Canada - English - Health Canada

juno pharmaceuticals corp. - dexamethasone phosphate (dexamethasone sodium phosphate) - solution - 4mg - dexamethasone phosphate (dexamethasone sodium phosphate) 4mg

Malta - English - Medicines Authority

rayner pharmaceuticals ltd 10 dominion way, worthing, west sussex, bn14 8aq,, united kingdom - dexamethasone phosphate - eye drops, solution - dexamethasone phosphate 1 mg/ml - ophthalmologicals

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - dexamethasone sodium phosphate (unii: ai9376y64p) (dexamethasone - unii:7s5i7g3jql) - - intravenous or intramuscular administration. when oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: endocrine disorders. primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is

Ireland - English - HPRA (Health Products Regulatory Authority)

hospira uk limited - dexamethasone sodium phosphate - solution for injection - 4 mg/ml - glucocorticoids

United States - English - NLM (National Library of Medicine)

pfizer laboratories div pfizer inc - dexamethasone sodium phosphate (unii: ai9376y64p) (dexamethasone - unii:7s5i7g3jql) - dexamethasone phosphate 4 mg in 1 ml

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - dexamethasone sodium phosphate (unii: ai9376y64p) (dexamethasone - unii:7s5i7g3jql) - dexamethasone phosphate 4 mg in 1 ml

United States - English - NLM (National Library of Medicine)

general injectables and vaccines, inc. - dexamethasone sodium phosphate (unii: ai9376y64p) (dexamethasone - unii:7s5i7g3jql) - dexamethasone phosphate 10 mg in 1 ml - a. by intravenous or intramuscular injection when oral therapy is not feasible: 1. endocrine disorders: primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. congenital adrenal hyperplasia. nonsuppurative thyroiditis. hypercalcemia associated with cancer. 2. rheumatic disorders: as adjunctive therapy for short-term administration (to tide the patient over an acute episode o

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - dexamethasone sodium phosphate 4.37 mg/ml equivalent to 4 mg dexamethasone phosphate - solution for injection - 4 mg/ml - active: dexamethasone sodium phosphate 4.37 mg/ml equivalent to 4 mg dexamethasone phosphate excipient: disodium edetate hydrochloric acid sodium citrate sodium hydroxide sodium sulfite water for injection - dexamethasone has predominantly glucocorticoid activity and therefore is not a complete replacement therapy in cases of adrenocortical insufficiency. dexamethasone should be supplemented with salt and/or a mineralocorticoid, such as deoxycorticosterone. when so supplemented, dexamethasone is indicated in: · acute adrenocortical insufficiency - addison's disease, bilateral adrenalectomy; · relative adrenocortical insufficiency - prolonged administration of adrenocortical steroids can produce dormancy of the adrenal cortex. the reduced secretory capacity gives rise to a state of relative adrenocortical insufficiency which persists for a varying length of time after therapy is discontinued. hould a patient be subjected to sudden stress during this period of reduced secretion (for up to two years after therapy has ceased) the steroid output may not be adequate. steroid therapy should therefore be reinstituted to help cope with stress such as that associated with surgery, trauma, burns, or severe infections where specific antibiotic therapy is available; · primary and secondary adrenocortical insufficiency.